Surrozen filings document a biotechnology issuer focused on Wnt signaling and antibody technologies for ophthalmic disease. Recent Form 8-K reports disclose operating results, financial condition, pipeline business updates for SZN-8141 and related retinal disease programs, and collaboration and license revenue tied to research milestones.
The company's regulatory reports also record governance and compensation matters, including board and executive changes and inducement equity arrangements, along with material-agreement disclosures such as the termination of the TCGFB collaboration for antibody discovery services. Cover-page data and exhibits identify Surrozen common stock and redeemable warrants as part of the public-company capital structure.
TCG Crossover investment entities reported open-market purchases of Surrozen, Inc. (SRZN) common stock. On January 30, 2026, TCG Crossover Fund II, L.P. bought 2,136 shares at $21.39 and TCG Crossover Fund III, L.P. bought 2,135 shares at $21.39, both indirectly held.
On February 2, 2026, Fund II purchased 366 shares at $21.38 and Fund III purchased 365 shares at $21.38. On February 3, 2026, Fund II bought 2,178 shares at $21.94, bringing its reported indirect holdings to 641,685 shares, while Fund III bought 2,177 shares at $21.94, bringing its reported indirect holdings to 641,682 shares.
TCG Crossover funds and Chen Yu report significant ownership in Surrozen, Inc. common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., through their general partners, each report beneficial ownership of 637,005 shares, or 5.7% of Surrozen’s common stock.
Chen Yu, as sole managing member of both general partners, reports beneficial ownership of 1,274,010 shares, representing 11.4% of the outstanding common stock based on 11,191,978 shares outstanding as of January 27, 2026. The filing states the securities were not acquired or held for the purpose of changing or influencing control of Surrozen.
Surrozen, Inc. reported that board member Shao-Lee Lin, M.D., Ph.D. resigned from its Board of Directors, effective immediately on January 26, 2026. The company stated that Dr. Lin’s resignation was not due to any disagreement regarding Surrozen’s operations, policies, or practices. Surrozen expressed appreciation for her service and dedication to the company’s mission.
Surrozen, Inc. (SRZN) received an initial ownership report showing that investment entities affiliated with TCG Crossover hold significant stakes in its common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., together with their general partners, each report indirect beneficial ownership of 637,005 shares of Surrozen common stock as of 01/26/2026. The funds hold the shares of record, while their general partners and Chen Yu, as sole managing member of each general partner, may be deemed to share voting, investment, and dispositive power over the reported securities.
Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received an employee stock option grant. On 01/23/2026, he was awarded options to purchase 500 shares of Surrozen common stock at an exercise price of $19.595 per share. These options expire on 01/22/2036 if not exercised.
The 500 options vest over four years in 48 equal monthly installments starting from the grant date, and are held directly by the executive. After this grant, he beneficially owns 500 derivative securities linked to Surrozen common stock.
Surrozen, Inc. received an amended Schedule 13D from venture capital firm The Column Group and related entities detailing their ownership of the company’s common stock. The filing shows that funds affiliated with The Column Group, together with managing partners Tim Kutzkey and Peter Svennilson, beneficially own 3,824,612 shares, or 35.1% of Surrozen’s common stock based on 10,885,617 shares outstanding.
The Column Group III GP, LP is reported as beneficially owning 2,962,544 shares, representing 28.6% of the class, while The Column Group III, LP and The Column Group III-A, LP report stakes of 14.2% and 15.9%, respectively. The Column Group Opportunity III–branded entities each report beneficial ownership of 862,068 shares, or 8.8% of the class.
The amendment also records a series of open-market purchases by TCG III LP and TCG III-A LP between November 13, 2025 and January 20, 2026 at prices ranging from $12.65 to $20.00 per share. Certain additional warrants are excluded from beneficial ownership because they are not exercisable within 60 days of the statement.
Surrozen, Inc. (SRZN) reported insider buying by investment funds affiliated with The Column Group. Multiple Column Group limited partnerships, each a 10% owner, disclosed open‑market purchases of Surrozen common stock on January 15, 16 and 20, 2026.
Examples include The Column Group III, LP buying 5,590 shares at $19.889 and 8,484 shares at $19.5999, and The Column Group III-A, LP buying 6,303 shares at $19.889 and 9,568 shares at $19.5999. Following these purchases, The Column Group III, LP reported beneficial ownership of 900,292 shares, The Column Group III-A, LP reported 1,016,658 shares, and The Column Group Opportunity III, LP reported holding 344,827 shares.
The filing notes that general partners and managing partners associated with these funds may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.
Surrozen, Inc. director and 10% owner Tim Kutzkey reported indirect open‑market purchases of the company’s common stock by investment funds he helps manage. Between January 15 and January 20, 2026, The Column Group III, LP and The Column Group III-A, LP bought a total of 32,507 shares at prices around $19.60–$20.00 per share. After these transactions, The Column Group III, LP held 900,292 shares, The Column Group III-A, LP held 1,016,658 shares, and The Column Group Opportunity III, LP held 344,827 shares, all reported as indirectly beneficially owned. The general partners and managing partners, including Kutzkey, disclaim beneficial ownership except to the extent of their pecuniary interest.
Surrozen, Inc. (SRZN) reported insider-related share purchases by investment funds affiliated with director and 10% owner Tim Kutzkey. On January 13, 2026, The Column Group III, LP bought 5,861 Surrozen common shares at $19.8041 each, bringing its indirect holdings to 882,418 shares, while The Column Group III-A, LP bought 6,609 shares at the same price, increasing its holdings to 996,502 shares.
On January 14, 2026, The Column Group III, LP purchased another 2,596 shares at $19.9883, and The Column Group III-A, LP purchased 2,927 shares at that price, raising their respective holdings to 885,014 and 999,429 shares. A related fund, The Column Group Opportunity III, LP, is shown holding 344,827 shares. The general partner entities and managing partners, including Kutzkey, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Surrozen, Inc. (SRZN) reported insider fund purchases of its common stock. Investment partnerships affiliated with The Column Group bought additional shares on January 13 and 14, 2026, in open-market transactions. The Column Group III, LP acquired 5,861 shares at $19.8041 and 2,596 shares at $19.9883, bringing its indirectly held position to 885,014 shares. The Column Group III-A, LP acquired 6,609 shares at $19.8041 and 2,927 shares at $19.9883, increasing its indirectly held position to 999,429 shares. A related fund, The Column Group Opportunity III, LP, is reported as indirectly holding 344,827 shares. The general partners and managing partners are listed as 10% owners and disclaim beneficial ownership beyond their pecuniary interests.